cystamine has been researched along with Disease Models, Animal in 28 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The hypothesis of the present study was that treatment with the transglutaminase inhibitor, cystamine, would inhibit the development of pulmonary arterial remodeling, pulmonary hypertension, and right ventricular hypertrophy." | 8.02 | Cystamine Treatment Fails to Prevent the Development of Pulmonary Hypertension in Chronic Hypoxic Rats. ( Aalling, M; Andersen, CU; Markvardsen, LK; Mogensen, S; Pinilla, E; Prat-Duran, J; Simonsen, U; Sønderskov, LD; Wandall-Frostholm, C, 2021) |
| "These data provide evidence to investigate the promising utility of cystamine for therapy of stroke in a variety of ways, acting principally through BDNF/TrkB pathway." | 7.81 | Cystamine improves functional recovery via axon remodeling and neuroprotection after stroke in mice. ( Chen, YC; Cui, Y; Ding, J; Jiao, Y; Ju, SH; Li, PC; Qian, C; Teng, GJ; Yang, XY; Yao, HH, 2015) |
| "Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations." | 6.47 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. ( Cicchetti, F; Gibrat, C, 2011) |
| "Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down-regulation of dopamine and cyclic adenosine monophsophate-regulated phosphoprotein (DARPP-32) expression in the striatum." | 5.33 | Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. ( Bailey, CD; Hayden, MR; Johnson, GV; Leavitt, BR; Pearson, J; Rogers, DA; Van Raamsdonk, JM, 2005) |
| " The hypothesis of the present study was that treatment with the transglutaminase inhibitor, cystamine, would inhibit the development of pulmonary arterial remodeling, pulmonary hypertension, and right ventricular hypertrophy." | 4.02 | Cystamine Treatment Fails to Prevent the Development of Pulmonary Hypertension in Chronic Hypoxic Rats. ( Aalling, M; Andersen, CU; Markvardsen, LK; Mogensen, S; Pinilla, E; Prat-Duran, J; Simonsen, U; Sønderskov, LD; Wandall-Frostholm, C, 2021) |
| "These data provide evidence to investigate the promising utility of cystamine for therapy of stroke in a variety of ways, acting principally through BDNF/TrkB pathway." | 3.81 | Cystamine improves functional recovery via axon remodeling and neuroprotection after stroke in mice. ( Chen, YC; Cui, Y; Ding, J; Jiao, Y; Ju, SH; Li, PC; Qian, C; Teng, GJ; Yang, XY; Yao, HH, 2015) |
| " Treatment in R6/2 transgenic HD mice, using the transglutaminase inhibitor cystamine, significantly extended survival, improved body weight and motor performance, and delayed the neuropathological sequela." | 3.71 | Therapeutic effects of cystamine in a murine model of Huntington's disease. ( Beal, MF; Bogdanov, M; Cooper, AJ; Dedeoglu, A; Ferrante, RJ; Hersch, SM; Jeitner, TM; Kowall, NW; Kubilus, JK; Matson, SA; Matson, WR; Ratan, RR, 2002) |
| "Neurodegenerative disorders are a subset of disabling pathologies characterized, in part, by a progressive and specific loss of certain brain cell populations." | 2.47 | Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. ( Cicchetti, F; Gibrat, C, 2011) |
| "Cystamine treatment of various genetic models of HD demonstrated protection against neurodegeneration and/or improvement in behavior." | 1.37 | Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. ( Leavitt, BR; Sivananthan, SN, 2011) |
| "Treatment with cystamine and garlic extract reduced the liver fibrosis and collagen deposition, particularly in the garlic extract group (p<0." | 1.36 | Garlic extract prevents CCl(4)-induced liver fibrosis in rats: The role of tissue transglutaminase. ( Amoruso, DC; Caporaso, N; D'Argenio, G; D'Armiento, MR; Fogliano, V; Mazzone, G; Mezza, E; Morisco, F; Ribecco, MT; Romano, A; Vitaglione, P, 2010) |
| "In a rat abdominal aortic aneurysm model using a combination of intraluminal elastase infusion and extraluminal calcium chloride, TG2 expression and activity were evaluated at 1 and 8 weeks after the AAA preparation (n = 6 at each endpoint), compared with those of the non-prepared aorta (n = 6)." | 1.36 | Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation. ( Hasegawa, T; Munezane, T; Okada, K; Okita, Y; Tanaka, A, 2010) |
| "Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down-regulation of dopamine and cyclic adenosine monophsophate-regulated phosphoprotein (DARPP-32) expression in the striatum." | 1.33 | Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. ( Bailey, CD; Hayden, MR; Johnson, GV; Leavitt, BR; Pearson, J; Rogers, DA; Van Raamsdonk, JM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 13 (46.43) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Markvardsen, LK | 1 |
| Sønderskov, LD | 1 |
| Wandall-Frostholm, C | 1 |
| Pinilla, E | 1 |
| Prat-Duran, J | 1 |
| Aalling, M | 1 |
| Mogensen, S | 1 |
| Andersen, CU | 1 |
| Simonsen, U | 1 |
| Chen, L | 1 |
| Liu, S | 1 |
| Xiao, L | 1 |
| Chen, K | 1 |
| Tang, J | 1 |
| Huang, C | 1 |
| Luo, W | 1 |
| Ferrandon, D | 1 |
| Lai, K | 1 |
| Li, Z | 1 |
| Philp, CJ | 1 |
| Siebeke, I | 1 |
| Clements, D | 1 |
| Miller, S | 1 |
| Habgood, A | 1 |
| John, AE | 1 |
| Navaratnam, V | 1 |
| Hubbard, RB | 1 |
| Jenkins, G | 1 |
| Johnson, SR | 1 |
| Li, PC | 1 |
| Jiao, Y | 1 |
| Ding, J | 1 |
| Chen, YC | 2 |
| Cui, Y | 1 |
| Qian, C | 1 |
| Yang, XY | 1 |
| Ju, SH | 1 |
| Yao, HH | 1 |
| Teng, GJ | 1 |
| Cisbani, G | 1 |
| Drouin-Ouellet, J | 1 |
| Gibrat, C | 3 |
| Saint-Pierre, M | 4 |
| Lagacé, M | 1 |
| Badrinarayanan, S | 1 |
| Lavallée-Bourget, MH | 1 |
| Charest, J | 1 |
| Chabrat, A | 1 |
| Boivin, L | 1 |
| Lebel, M | 1 |
| Bousquet, M | 2 |
| Lévesque, M | 1 |
| Cicchetti, F | 5 |
| Hsu, TC | 3 |
| Lai, WX | 2 |
| Chiang, SY | 2 |
| Huang, CY | 2 |
| Tzang, BS | 3 |
| Wang, HP | 1 |
| Hsu, GJ | 1 |
| Li, SL | 1 |
| Li, X | 1 |
| Wei, XL | 1 |
| Meng, LL | 1 |
| Chi, MG | 1 |
| Yan, JQ | 1 |
| Ma, XY | 1 |
| Jia, YS | 1 |
| Liang, L | 1 |
| Yan, HT | 1 |
| Zheng, JQ | 1 |
| Lévesque, D | 2 |
| Calon, F | 1 |
| Rouillard, C | 2 |
| D'Argenio, G | 1 |
| Amoruso, DC | 1 |
| Mazzone, G | 1 |
| Vitaglione, P | 1 |
| Romano, A | 1 |
| Ribecco, MT | 1 |
| D'Armiento, MR | 1 |
| Mezza, E | 1 |
| Morisco, F | 1 |
| Fogliano, V | 1 |
| Caporaso, N | 1 |
| Bortvedt, SF | 1 |
| McLear, JA | 1 |
| Messer, A | 1 |
| Ahern-Rindell, AJ | 1 |
| Wolfgang, WJ | 1 |
| Davies, JE | 1 |
| Rose, C | 1 |
| Sarkar, S | 1 |
| Rubinsztein, DC | 1 |
| Munezane, T | 1 |
| Hasegawa, T | 1 |
| Tanaka, A | 1 |
| Okada, K | 1 |
| Okita, Y | 1 |
| Sivananthan, SN | 1 |
| Leavitt, BR | 2 |
| Dedeoglu, A | 1 |
| Kubilus, JK | 1 |
| Jeitner, TM | 1 |
| Matson, SA | 1 |
| Bogdanov, M | 1 |
| Kowall, NW | 1 |
| Matson, WR | 2 |
| Cooper, AJ | 1 |
| Ratan, RR | 1 |
| Beal, MF | 1 |
| Hersch, SM | 2 |
| Ferrante, RJ | 3 |
| Fox, JH | 1 |
| Barber, DS | 1 |
| Singh, B | 1 |
| Zucker, B | 1 |
| Swindell, MK | 1 |
| Norflus, F | 1 |
| Buzescu, R | 1 |
| Chopra, R | 1 |
| Kazantsev, A | 1 |
| Wang, X | 1 |
| Sarkar, A | 1 |
| Yu, M | 1 |
| Zhu, A | 1 |
| Jokivarsi, K | 1 |
| Brownell, AL | 1 |
| Bailey, CD | 2 |
| Johnson, GV | 2 |
| Tremblay, ME | 1 |
| Bourhis, E | 1 |
| Van Raamsdonk, JM | 1 |
| Pearson, J | 1 |
| Rogers, DA | 1 |
| Hayden, MR | 1 |
| Eftekhari, A | 1 |
| Rahman, A | 1 |
| Schaebel, LH | 1 |
| Chen, H | 1 |
| Rasmussen, CV | 1 |
| Aalkjaer, C | 1 |
| Buus, CL | 1 |
| Mulvany, MJ | 1 |
| Tsai, CH | 1 |
| Stack, EC | 1 |
| Ferro, JL | 1 |
| Kim, J | 1 |
| Del Signore, SJ | 1 |
| Goodrich, S | 1 |
| Matson, S | 1 |
| Hunt, BB | 1 |
| Cormier, K | 1 |
| Smith, K | 1 |
| Ryu, H | 1 |
| Roisin-Bouffay, C | 1 |
| Castellano, R | 1 |
| Valéro, R | 1 |
| Chasson, L | 1 |
| Galland, F | 1 |
| Naquet, P | 1 |
| Shenberg, C | 1 |
| Boazi, M | 1 |
| Cohen, J | 1 |
| Klein, A | 1 |
| Kojler, M | 1 |
| Nyska, A | 1 |
1 review available for cystamine and Disease Models, Animal
| Article | Year |
|---|---|
Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.
Topics: Animals; Cystamine; Cysteamine; Disease Models, Animal; Enzyme Inhibitors; Humans; Huntington Diseas | 2011 |
27 other studies available for cystamine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Cystamine Treatment Fails to Prevent the Development of Pulmonary Hypertension in Chronic Hypoxic Rats.
Topics: Animals; Arterial Pressure; Cystamine; Disease Models, Animal; Enzyme Inhibitors; Female; Hypertensi | 2021 |
An initial assessment of the involvement of transglutaminase2 in eosinophilic bronchitis using a disease model developed in C57BL/6 mice.
Topics: Animals; Asthma; Bronchitis; Cystamine; Cytokines; Disease Models, Animal; Eosinophils; Gene Express | 2021 |
Extracellular Matrix Cross-Linking Enhances Fibroblast Growth and Protects against Matrix Proteolysis in Lung Fibrosis.
Topics: Airway Remodeling; Amino Acid Oxidoreductases; Animals; Bleomycin; Cell Adhesion; Cell Proliferation | 2018 |
Cystamine improves functional recovery via axon remodeling and neuroprotection after stroke in mice.
Topics: Animals; Axons; Azepines; Benzamides; Brain; Brain Ischemia; Cell Survival; Central Nervous System A | 2015 |
Cystamine/cysteamine rescues the dopaminergic system and shows neurorestorative properties in an animal model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Astrocytes; Cell Line; Cells, Cultured; Corpus Striatum; Cystamine; C | 2015 |
Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice.
Topics: Animals; Apoptosis; Brain; Cystamine; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Reg | 2008 |
Cystamine attenuates the expressions of NOS- and TLR-associated molecules in the brain of NZB/W F1 mice.
Topics: Animals; Brain; Cyclin-Dependent Kinase Inhibitor p21; Cystamine; Disease Models, Animal; Female; Ge | 2009 |
Involvement of tissue transglutaminase in endothelin 1-induced hypertrophy in cultured neonatal rat cardiomyocytes.
Topics: Animals; Animals, Newborn; Cadaverine; Cells, Cultured; Cystamine; Disease Models, Animal; Dose-Resp | 2009 |
Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor.
Topics: Analysis of Variance; Animals; Brain; Brain-Derived Neurotrophic Factor; Cell Count; Cystamine; Dise | 2010 |
Garlic extract prevents CCl(4)-induced liver fibrosis in rats: The role of tissue transglutaminase.
Topics: Actins; Animals; Carbon Tetrachloride; Collagen; Cystamine; Disease Models, Animal; Down-Regulation; | 2010 |
Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.
Topics: Animals; Animals, Genetically Modified; Antibodies; Cystamine; Disease Models, Animal; Drosophila me | 2010 |
Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Topics: Animals; Apoptosis; Biomarkers; Cell Line; Cystamine; Cytoprotection; Disease Models, Animal; Gene K | 2010 |
Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Calcium Chloride; Cystamine; Disease Models, | 2010 |
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disea | 2011 |
Therapeutic effects of cystamine in a murine model of Huntington's disease.
Topics: Administration, Oral; Aged; Animals; Behavior, Animal; Biomarkers; Body Weight; Caudate Nucleus; Cys | 2002 |
Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Topics: Animals; Antioxidants; Brain; Buthionine Sulfoximine; Cystamine; Cysteine; Cytoprotection; Disease M | 2004 |
Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.
Topics: Age Factors; Animals; Binding, Competitive; Body Weight; Brain; Brain Chemistry; Brain Mapping; Cere | 2005 |
The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
Topics: Age Factors; Age of Onset; Animals; Body Weight; Cystamine; Disease Models, Animal; Disease Progress | 2006 |
Neuroprotective effects of cystamine in aged parkinsonian mice.
Topics: Aging; Animals; Cell Count; Corpus Striatum; Cystamine; Disease Models, Animal; Dopamine Plasma Memb | 2006 |
Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
Topics: Administration, Oral; Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Drug Administrati | 2005 |
Chronic cystamine treatment inhibits small artery remodelling in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Collagen; Cystamine; Disease Models, A | 2007 |
Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cystamine; Disease Models, Animal; Enzym | 2008 |
Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cystamine; Disease Models, Animal; Dru | 2008 |
Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes.
Topics: Amidohydrolases; Animals; Cell Adhesion Molecules; Cell Death; Cells, Cultured; Cystamine; Diabetes | 2008 |
An XRF study of trace elements accumulation in kidneys of tumor-bearing mice after treatment with cis-DDP with and without selenite and selenocistamine.
Topics: Animals; Cisplatin; Copper; Cystamine; Disease Models, Animal; Humans; Iron; Kidney; Male; Mice; Mic | 1994 |